Drug
Efgartigimod Alfa
Efgartigimod Alfa: highest development phase Phase 2, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod Alfa NCT06453694 | Phase 2 | Optic Neuritis |
Latest
No recent events.
Follow Efgartigimod Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.